Autonomix Medical Files 10-K Amendment
Ticker: AMIX · Form: 10-K/A · Filed: Jul 26, 2024 · CIK: 1617867
Sentiment: neutral
Topics: amendment, annual-report, medical-devices
TL;DR
Autonomix Medical filed a 10-K/A for FY24 ending March 31. Check for updates.
AI Summary
Autonomix Medical, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended March 31, 2024. The filing, dated July 26, 2024, provides updated information regarding the company's operations and financial status. Autonomix Medical, Inc. is incorporated in Delaware and operates in the surgical and medical instruments sector.
Why It Matters
This amendment provides updated financial and operational details for Autonomix Medical, Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous annual report and does not appear to contain new material adverse information.
Key Numbers
- 001-41940 — SEC File Number (Identifies the company's filings with the SEC.)
- 47-1607810 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Autonomix Medical, Inc. (company) — Registrant
- March 31, 2024 (date) — Fiscal year end
- July 26, 2024 (date) — Filing date
- Delaware (location) — State of Incorporation
- 3841 (industry_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this 10-K/A filing?
This 10-K/A filing serves as an amendment to Autonomix Medical, Inc.'s annual report for the fiscal year ended March 31, 2024, providing updated information.
When is the fiscal year end for Autonomix Medical, Inc. as reported in this filing?
The fiscal year end for Autonomix Medical, Inc. is March 31, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 21 Waterway Avenue, Suite 300, The Woodlands, Texas 77380.
In which state is Autonomix Medical, Inc. incorporated?
Autonomix Medical, Inc. is incorporated in Delaware.
What is the Standard Industrial Classification code for Autonomix Medical, Inc.?
The Standard Industrial Classification code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 4,537 words · 18 min read · ~15 pages · Grade level 12 · Accepted 2024-07-26 17:14:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value AMIX The Nasdaq Stock Mar
- $36 billion — otal market capitalization greater than $36 billion. As a businessman, Dr. Capelli has been
Filing Documents
- amix20240331_10ka.htm (10-K/A) — 329KB
- ex_703233.htm (EX-31.3) — 4KB
- ex_703234.htm (EX-31.4) — 4KB
- autonomix01.jpg (GRAPHIC) — 5KB
- 0001437749-24-023626.txt ( ) — 586KB
- amix-20240331.xsd (EX-101.SCH) — 3KB
- amix-20240331_def.xml (EX-101.DEF) — 16KB
- amix-20240331_lab.xml (EX-101.LAB) — 23KB
- amix-20240331_pre.xml (EX-101.PRE) — 17KB
- amix20240331_10ka_htm.xml (XML) — 7KB
Executive Compensation
Executive Compensation 9 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 14 Item 13. Certain Relationships and Related Transactions and Director Independence 16 Item 14. Principal Accounting Fees and Services 17 PART IV Item 15. Exhibits, Financial Statement Schedules 18 3 Table of Contents PART III
Directors, Executive Officers and Corporate Governance
Item 10. Directors, Executive Officers and Corporate Governance Directors and Executive Officers The following table sets forth the names and ages of all of our directors and executive officers as of July 22, 2024. Our officers are appointed by, and serve at the pleasure of, the Board of Directors. Name Age Position Brad Hauser 47 Chief Executive Officer Dr. Robert Schwartz 73 Chief Medical Officer Landy Toth 47 Chief Technology Officer Trent Smith 55 Chief Financial Officer Walter V. Klemp 65 Executive Chairman Lori Bisson 54 Vice Chair and Director Jonathan P. Foster 60 Director David Robins 55 Director Christopher Capelli 64 Director Set forth below is biographical information about each of the individuals named in the table above: Brad Hauser, Chief Executive Officer . Mr. Hauser joined us in June 2024 as our Chief Executive Officer and President. Prior to his appointment, Mr. Hauser served as the Chief Operating Officer at Beauty Health from January 2023 to June 2024. Mr. Hauser previously served as the President and Chief Executive Officer at Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics, from November 2020 to December 2021. Soliton was purchased by AbbVie in 2021 and he continued to provide transition support post-acquisition as the President and Chief Executive Officer of Soliton with Allergan Aesthetics, an AbbVie company, until July 2022. Mr. Hauser previously served as Vice President, Research and Development and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired by Allergan in April 2017. Previously, he served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to